Systemic AA amyloidosis induced by benign neoplasms;Amiloidosis secundaria (AA) asociada a tumoraciones benignas

Nefrologia

Volumn 28, Issue 1, 2008, Pages 93-98

  Bestard Matamoros, Oriol ^a   Poveda Monje, R ^a   Ibernon Vilaro M ^a   Carrera Plans, M ^a   Grinyo Boira J M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Benign neoplasms; Castleman's disease; Hepatic adenoma; Nephrotic syndrome; Secondary amyloidosis (AA), oral contraceptives

Indexed keywords

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; FEMALE; HUMAN; NEOPLASM;

ADULT; AMYLOIDOSIS; FEMALE; HUMANS; NEOPLASMS;

EID: 47049131721     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Gillmore, JD, Lovat, LB, Persey, MR y cols. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 7; 358 (9275): 24-9. 2001.
2. Westermark, GT, Sletten, K, Westermark, P. Massive vascular AAamyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 30 (5): 605-13,1989.
3. Gómez-Casanovas, E, Sanmarti, R, Sole, M y cols. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 44 (1): 66-72, 2001.
4. Wakhlu, A, Krisnani, N, Hissaria, P y cols. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 31 (5): 1013-4, 2003.
5. El Mansoury, TM, Hazenberg, BP, El Badawy, SA y cols. Screening for amyloid in subcutaneous tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 61: 42.5455, 2002.
6. Wiland, P, Wojtala, R, Goodacre, J, Szechinski, J. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol 23 (3): 193-8, 2004.
7. McAdam, KP, Raynes, JG, Alpers, MP y cols. Amyloidosis: a global problem common in Papua New Guinea. PNG Med J 39 (4): 284-96, 1996.
8. Tuglular, S, Yalcinkaya, F, Paydas, S y cols. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 17: 2003, 2002.
9. Cosme A, Horcajada JP, Vidaur F, Ojeda E, Torrado J, Arenas JI. Systemic AA amyloidosis induced by oral contraceptive-associated hepatocellular adenoma: a 13-year follow up. Liver 15 (3): 164-7, 1995.
10. Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 27; 2 (7835): 926-9, 1973.
11. Edmondson, HA, Henderson, B, Benton, B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 26; 294 (9): 470-2, 1976.
12. Rooks, JB, Ory, HW, Ishak, KG y cols. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 17; 242 (7): 644-8, 1979.
13. Klatskin, G. Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology 73 (2): 386-94, 1977.
14. Soe, KL, Soe, M, Gluud, C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 12 (2): 73-9, 1992.
15. Shortell, CK, Schwartz, SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet 174 (5): 403-7, 1991.
16. Meissner, K. Hemorrhage caused by ruptured liver cell adenoma following long-term oral contraceptives: a case report. Hepatogastroenterology 45 (19): 224-5, 1998.
17. Edmondson, HA, Reynolds, TB, Henderson, B, Benton, B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 86: 180, 1977.
18. Kawakatsu, M, Vilgrain, V, Erlinger, S, Nahum, H. Disappearance of liver cell adenoma: CT and MR imaging. Abdom Imaging 86 (2): 180-2, 1997.
19. Aseni, P, Sansalone, CV, Sammartino, C y cols. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 33 (3): 234-6, 2001.
20. Norris, S. Drug- and Toxin-Induced Liver Injury. En: Comprehensive Clinical Hepatology, O'Grady, J, Lake, J, Howdle, P (Eds), Harcourt Publishers Limited, London 2000. p. 1.
21. Kerlin, P, Davis, GL, McGill, DB, y cols. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 84 (5 Pt 1): 994-1002, 1983.
22. Foster, JH, Berman, MM. The malignant transformation of liver cell adenomas. Arch Surg 129 (7): 712-7, 1994.
23. Sherlock, S. Hepatic reactions to drugs. Gut; 20 (7): 634-48, 1979.
24. Malt, RA. Surgery for hepatic neoplasms. N Engl J Med 19; 313 (25): 1591-6, 1985.
25. Ault, GT, Wren, SM, Ralls, PW y cols. Selective management of hepatic adenomas. Am Surg 62 (10): 825-9, 1996.
26. Foster, JH, Berman, MM. The malignant transformation of liver cell adenomas. Arch Surg 129 (7): 712-7, 1994.
27. Shibasaki T, Matsumoto H y cols. A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumor necrosis factor-alpha. Nephron 75 (3): 350-3, 1997.
28. Cosme A, Horcajada JP, Vidaur F, Ojeda E, Torrado J, Arenas JI. Systemic AA amyloidosis induced by oral contraceptive-associated hepatocellular adenoma: a 13-year follow up. Liver 15 (3): 164-7, 1995.
29. Frizzera G, Massarelli G, Banks PM y cols. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7: 211-231, 1983.
30. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S.Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2 (6): 344-52, 2002.
31. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Clin Infect Dis 1;35 (7): 880-2, 2002.
32. Keven K, Nergizoglu G, Ales K y cols. Remission of nephrotic syndrome after removal of localized Castleman's disease. Am J Kidney Dis 35: 1207-1211, 2000.
33. Lui SL, Chan KW, Li FK, Cheng IKP, Chan TM. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 78: 323-327, 1998.
34. Beck JT, Hsu SM, Wijdenes J y cols. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330: 602-605, 1994.
35. Curioni S, D'Amico M, Quartagno R, Martino S, Dell'Antonio G, Cusi D. Castleman's disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant 16 (7): 1475-8, 2001.
36. Perfetti V, Bellotti V, Maggi A y cols. Reversal of nephrotic syndrome due to reactive amyloidosis after excision of localized Castleman's disease. Am J Hematol 46: 189-193, 1994.
37. Kazes I, Deray G, Jacobs C. Castleman's disease and renal amyloidosis. Ann Intern Med 71: 463-464, 1995.
38. Arinsoy T, Yilmaz M, Atao lu Ö, Bali M, Sindel S. Castleman's disease with renal amyloidosis and nephrotic syndrome. Nephrol Dial Transplant 12: 2713-2716, 1997.
39. Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease. Nephron 71: 463-464, 1995.